A Phase 2 interventional study of Tislelizumab in Peripheral T Cell Lymphoma, PTCL and Extranodal NK/T-cell Lymphoma, sponsored by BeiGene. Completed at 24 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Lymphoma, T-Cell, Peripheral with a site in China — 64 open to participants now, 70 under way, 10 of them phase 3. Lymphoma, T-Cell, Peripheral · China.
Among the 114 studies in Lymphoma, T-Cell, Peripheral with a site in China, this one is the 40th largest by enrollment of the 106 interventional ones that give a count, is one of 4 that started in 2018, is one of 38 in phase 2, and was the 17th registered.
372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.
Browse Lymphoma, T-Cell, Peripheral studies →64 of the 114 studies in Lymphoma, T-Cell, Peripheral with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital of Soochow University · Sites in China
Ages 18–75
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75
Fudan University · Sites in China
Ages 18+
Beijing Biotech · Sites in China
Ages 18–75
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 64 · Phase 3 13 · Phase 4 3
First in 2006; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is above the median of 44 across 328 interventional studies indexed under Lymphoma, T-Cell, Peripheral.
Median enrollment 50 across the 106 interventional studies, 230 across the 8 observational. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 114 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 1 study filed under Lymphoma, T-Cell, Peripheral — fewer than ten, so there is no comparison to draw.
10 of the studies in Lymphoma, T-Cell, Peripheral with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07234162Phase 3Dizal PharmaceuticalsA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) | 2027-11-30 |
| NCT06855823Sun Yat-sen UniversityA Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL | 2026-12 |
| NCT04512534Fudan UniversitySintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma | 2026-12-01 |
| NCT05958719Institute of Hematology & Blood Diseases Hospital, ChinaChidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma | 2026-12-30 |
| NCT06151106The First Affiliated Hospital of Xiamen UniversityChidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 114 studies in Lymphoma, T-Cell, Peripheral with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in participants with relapsed or refractory mature T- and natural killer (NK)-cell neoplasms. There were three cohorts:
Study procedures included a Screening phase (up to 35 days); Treatment phase (until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first); Safety Follow-up phase (up to 90 days following last study treatment for all adverse events (AEs) and serious adverse events (SAEs)); and Survival follow-up phase (duration varying by participant).
Key Inclusion Criteria
Key Exclusion Criteria
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
Drug: Tislelizumab
Participants with other R/R mature T-cell neoplasms \[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
Drug: Tislelizumab
Participants with R/R cutaneous T-cell lymphoma \[limited to mycosis fungoides (MF) and Sèzary syndrome (SS)\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
Drug: Tislelizumab
Administered intravenously
Also known as: BGB-A317
Overall Response Rate (ORR)
ORR is defined as the percentage of participants achieving a best overall response of complete response or partial response as determined by the investigator using Lugano criteria with Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) modification for cohorts 1 and 2 and International Society for Cutaneous Lymphomas/European Organization of Research and Treatment of Cancer (ISCL/EORTC) guidelines for cohort 3.
Time frame: Up to approximately 3 years and 1 week
Duration of Response (DOR)
DOR defined as the time from the first determination of an objective response until progression or death, whichever occurs first, as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
Time frame: Up to approximately 3 years and 1 week
Progression-free Survival (PFS)
PFS is defined as the time from first study drug administration to the date of disease progression or death, whichever occurs first, as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
Time frame: Up to approximately 3 years and 1 week
Overall Survival (OS)
OS defined as the time from first study drug administration to the date of death due to any reason for cohorts 1 and 2.
Time frame: Up to approximately 3 years and 1 week
Complete Response Rate (CRR)
CRR is defined as the percentage of participants who achieve complete response or complete metabolic response as best overall response as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
Time frame: Up to approximately 3 years and 1 week
Time to Response (TTR)
Time to response defined as the time from first study drug administration to the time the response criteria (complete response or partial response) are first met as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
Time frame: Up to approximately 3 years and 1 week
Quality of Life Assessment: EQ-5D-5L Change From Baseline in Visual Analogue Score
Mean change from baseline at safety follow-up visit in EQ-5D-5L visual analogue score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' An increasing score indicates improvements from baseline.
Time frame: Baseline and on Day 1 in Cycles 5, 9, 13, 17, 21, 25, 29, and 33 (21 days per cycle) and safety follow-up visit (up to 30 days after end of treatment; up to approximately 3 years and 1 week)
Quality of Life Assessment: EORTC QLQ-C30 Change From Baseline in Global Health Status Score
Mean change from baseline at safety follow-up visit in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes global health status and quality of life questions related to their overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a higher score indicating improved health status.
Time frame: Baseline and on Day 1 in Cycles 5, 9, 13, 17, 21, 25, 29, and 33 (21 days per cycle) and safety follow-up visit (up to 30 days after end of treatment; up to approximately 3 years and 1 week)
Quality of Life Assessment: EORTC QLQ-C30 Change From Baseline in Fatigue Score
Mean change from baseline at safety follow-up visit in EORTC QLQ-C30 Fatigue score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes questions related to fatigue symptoms in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a higher score indicating improved health status.
Time frame: Baseline and on Day 1 in Cycles 5, 9, 13, 17, 21, 25, 29, and 33 (21 days per cycle) and safety follow-up visit (up to 30 days after end of treatment; up to approximately 3 years and 1 week)
Number of Participants With Adverse Events
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically relevant changes in laboratory tests, physical examination, electrocardiogram, and vital signs
Time frame: Up to approximately 3 years and 1 week
Participants were enrolled from study centers in Canada, China, France, Italy, and Taiwan, China.
| Milestone | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS |
|---|---|---|---|
| Started | 22 | 44 | 11 |
| Completed | 0 | 0 | 0 |
| Not completed | 22 | 44 | 11 |
| Withdrew: Death | 11 | 26 | 3 |
| Withdrew: Lost to follow-up | 1 | 4 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 |
| Withdrew: Progressive disease | 1 | 0 | 0 |
| Withdrew: Transferred to long term extension study | 8 | 13 | 5 |
ORR is defined as the percentage of participants achieving a best overall response of complete response or partial response as determined by the investigator using Lugano criteria with Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) modification for cohorts 1 and 2 and International Society for Cutaneous Lymphomas/European Organization of Research and Treatment of Cancer (ISCL/EORTC) guidelines for cohort 3.
| Percentage of participants | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS |
|---|---|---|---|
| Overall Response Rate (ORR) | 31.8 (13.9 to 54.9) | 20.5 (9.8 to 35.3) | 45.5 (16.7 to 76.6) |
DOR defined as the time from the first determination of an objective response until progression or death, whichever occurs first, as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
| Months | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS |
|---|---|---|---|
| Duration of Response (DOR) | NA (2.66 to NA) | 8.2 (2.50 to NA) | 11.3 (2.76 to 11.30) |
PFS is defined as the time from first study drug administration to the date of disease progression or death, whichever occurs first, as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
| Months | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS |
|---|---|---|---|
| Progression-free Survival (PFS) | 2.7 (1.45 to 5.32) | 2.7 (2.56 to 4.76) | 16.8 (2.60 to 16.82) |
OS defined as the time from first study drug administration to the date of death due to any reason for cohorts 1 and 2.
| Months | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL |
|---|---|---|
| Overall Survival (OS) | 8.8 (3.25 to NA) | 13.3 (7.66 to 26.22) |
CRR is defined as the percentage of participants who achieve complete response or complete metabolic response as best overall response as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
| Percentage of participants | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS |
|---|---|---|---|
| Complete Response Rate (CRR) | 18.2 (5.2 to 40.3) | 9.1 (2.5 to 21.7) | 9.1 (0.2 to 41.3) |
Time to response defined as the time from first study drug administration to the time the response criteria (complete response or partial response) are first met as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
| Months | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS |
|---|---|---|---|
| Time to Response (TTR) | 5.75 (2.1 to 13.9) | 2.86 (2.1 to 5.5) | 6.83 (2.6 to 11.1) |
Mean change from baseline at safety follow-up visit in EQ-5D-5L visual analogue score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' An increasing score indicates improvements from baseline.
| Score on a scale | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS |
|---|---|---|---|
| Cycle 5, Day 1 | 4.42 ± 10.273 | 1.11 ± 13.884 | 0.25 ± 22.276 |
| Cycle 9, Day 1 | 1.17 ± 4.916 | 5.56 ± 21.279 | -0.83 ± 17.713 |
| Cycle 13, Day 1 | -3.29 ± 16.650 | 15.00 ± 19.685 | 1.33 ± 21.398 |
| Cycle 17, Day 1 | 0.17 ± 9.326 | 10.00 ± 17.889 | 3.67 ± 23.551 |
| Cycle 21, Day 1 | 4.25 ± 10.905 | 8.33 ± 22.546 | 5.50 ± 18.285 |
| Cycle 25, Day 1 | 4.00 ± 14.422 | -2.50 ± 10.607 | 5.00 ± 7.071 |
| Cycle 29, Day 1 | -2.67 ± 4.619 | -5.00 ± 7.071 | — |
| Cycle 33, Day 1 | -3.00 ± NA | 0.00 ± NA | — |
| Safety Follow-up | -1.50 ± 8.546 | -9.52 ± 21.047 | 12.50 ± 3.536 |
Mean change from baseline at safety follow-up visit in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes global health status and quality of life questions related to their overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a higher score indicating improved health status.
| Score on a scale | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS |
|---|---|---|---|
| Cycle 5, Day 1 | 7.64 ± 24.220 | 6.67 ± 19.041 | 10.42 ± 24.296 |
| Cycle 9, Day 1 | 8.33 ± 10.541 | 12.04 ± 28.294 | 1.39 ± 21.995 |
| Cycle 13, Day 1 | 4.76 ± 11.644 | -1.67 ± 19.003 | 2.78 ± 15.516 |
| Cycle 17, Day 1 | 2.78 ± 12.546 | 6.94 ± 30.008 | 4.17 ± 21.570 |
| Cycle 21, Day 1 | 12.50 ± 14.434 | 0.00 ± 33.333 | 0.00 ± 20.412 |
| Cycle 25, Day 1 | 14.58 ± 25.797 | -8.33 ± 11.785 | -4.17 ± 5.893 |
| Cycle 29, Day 1 | 16.67 ± 16.667 | -8.33 ± 11.785 | — |
| Cycle 33, Day 1 | 0.00 ± NA | 0.00 ± NA | — |
| Safety Follow-up | 7.74 ± 27.045 | -14.93 ± 26.917 | 20.83 ± 17.678 |
Mean change from baseline at safety follow-up visit in EORTC QLQ-C30 Fatigue score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes questions related to fatigue symptoms in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a higher score indicating improved health status.
| Score on a scale | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS |
|---|---|---|---|
| Cycle 5, Day 1 | -2.78 ± 14.312 | 7.02 ± 14.912 | 1.39 ± 41.335 |
| Cycle 9, Day 1 | 0.00 ± 12.172 | -1.39 ± 11.011 | -22.22 ± 41.574 |
| Cycle 13, Day 1 | -1.59 ± 11.878 | -6.67 ± 12.669 | -5.56 ± 18.257 |
| Cycle 17, Day 1 | 9.26 ± 16.355 | 1.85 ± 10.924 | -12.96 ± 16.355 |
| Cycle 21, Day 1 | 0.00 ± 12.830 | 11.11 ± 11.111 | -16.67 ± 14.344 |
| Cycle 25, Day 1 | 0.00 ± 15.713 | 27.78 ± 7.857 | -5.56 ± 7.857 |
| Cycle 29, Day 1 | 3.70 ± 27.962 | 22.22 ± 15.713 | — |
| Cycle 33, Day 1 | 11.11 ± NA | 33.33 ± NA | — |
| Safety Follow-up | -1.59 ± 19.903 | 7.87 ± 30.820 | -44.44 ± 31.427 |
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically relevant changes in laboratory tests, physical examination, electrocardiogram, and vital signs
| Participants | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS |
|---|---|---|---|
| At least one TEAE | 22 | 41 | 10 |
| SAEs | 9 | 21 | 5 |
Collected over Up to approximately 3 years and 1 week. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: ENKTL | 11/22 (50%) | 9/22 (40.9%) | 21/22 (95.5%) |
| Cohort 2: PTCL-NOS, AITL, and ALCL | 26/44 (59.1%) | 21/44 (47.7%) | 39/44 (88.6%) |
| Cohort 3: MF and SS | 3/11 (27.3%) | 5/11 (45.5%) | 10/11 (90.9%) |
| Event | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS |
|---|---|---|---|
| Cardiac failureCardiac disorders | 0/22 | 0/44 | 1/11 |
| PyrexiaGeneral disorders | 0/22 | 4/44 | 0/11 |
| Cellulitis staphylococcalInfections and infestations | 0/22 | 0/44 | 1/11 |
| PneumoniaInfections and infestations | 2/22 | 4/44 | 0/11 |
| Pneumonia cryptococcalInfections and infestations | 0/22 | 0/44 | 1/11 |
| Staphylococcal sepsisInfections and infestations | 0/22 | 0/44 | 1/11 |
| Varicella zoster virus infectionInfections and infestations | 0/22 | 0/44 | 1/11 |
| DizzinessNervous system disorders | 0/22 | 0/44 | 1/11 |
| SyncopeNervous system disorders | 0/22 | 1/44 | 1/11 |
| Renal impairmentRenal and urinary disorders | 0/22 | 1/44 | 1/11 |
| Event | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/22 | 4/44 | 4/11 |
| Oedema peripheralGeneral disorders | 2/22 | 3/44 | 4/11 |
| PyrexiaGeneral disorders | 6/22 | 13/44 | 4/11 |
| AnaemiaBlood and lymphatic system disorders | 6/22 | 7/44 | 0/11 |
| HypothyroidismEndocrine disorders | 1/22 | 5/44 | 3/11 |
| VomitingGastrointestinal disorders | 2/22 | 0/44 | 3/11 |
| Influenza like illnessGeneral disorders | 0/22 | 1/44 | 3/11 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/22 | 7/44 | 3/11 |
| PruritusSkin and subcutaneous tissue disorders | 2/22 | 6/44 | 3/11 |
| RashSkin and subcutaneous tissue disorders | 1/22 | 2/44 | 3/11 |
| Age, Continuous(Years) | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS | Total |
|---|---|---|---|---|
| Mean | 51.5 ± 16.24 | 55.8 ± 15.03 | 59.4 ± 12.45 | 55.1 ± 15.09 |
| Sex: Female, Male(Participants) | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS | Total |
|---|---|---|---|---|
| Female | 8 | 15 | 3 | 26 |
| Male | 14 | 29 | 8 | 51 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS | Total |
|---|---|---|---|---|
| Asian | 19 | 23 | 2 | 44 |
| White | 2 | 18 | 8 | 28 |
| Not Reported | 1 | 3 | 1 | 5 |
| Region of Enrollment(Participants) | Cohort 1: ENKTL | Cohort 2: PTCL-NOS, AITL, and ALCL | Cohort 3: MF and SS | Total |
|---|---|---|---|---|
| Canada | 0 | 0 | 2 | 2 |
| China | 19 | 22 | 0 | 41 |
| Taiwan | 0 | 1 | 0 | 1 |
| Italy | 2 | 18 | 8 | 28 |
| France | 1 | 3 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Apr 2018 to primary completion in Apr 2021, 36 months.
Results were first posted in May 2022, 1 year after primary completion.
Of 64 phase 2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 96. This study's 36 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab
Lymphoma, T-Cell, Peripheral →